Pharma & Biotech - Page 13

The US Food and Drug Administration has moved into full enforcement of the Drug Supply Chain Security Act after an 18-month stabilisation grace period concluded. The enforcement shift marks a significant turning

Ember LifeSciences has entered into a capital and business alliance with Alfresa Corporation to strengthen pharmaceutical cold chain logistics across Japan. Alfresa Corporation is a subsidiary of Alfresa Holdings Corporation, which holds

Pharmaceutical manufacturers are accelerating investment in direct-to-patient models as policy shifts and rising consumer expectations reshape the industry landscape. Chip Parkinson, CEO of Gifthealth, says the momentum behind these integrated models has

Incyte Corporation has raised its full-year 2026 Opzelura net sales guidance to between $1.05 billion and $1.1 billion following a landmark settlement with the Centers for Medicare & Medicaid Services. The agreement

Biogen has dramatically reversed its 2026 revenue guidance, shifting from an anticipated mid-single-digit percentage decrease to an expected mid-single-digit percentage increase. The pharmaceutical company reported second-quarter 2026 total revenue of $2.7 billion,

Colonis Pharma Limited has been sanctioned by the Prescription Medicines Code of Practice Authority over a promotional letter for its Melatonin 1mg/ml Oral Solution product. The PMCPA ruled the letter breached multiple

CG Life, the PE-backed scientific commercialisation agency founded in 2003, has agreed to merge with AI-native agency The Considered+AI in a deal announced this week. Financial terms of the acquisition were not

GSK has unveiled a sweeping three-year cost-savings programme worth £1.9 billion, equivalent to around $2.5 billion, aimed at reshaping how the British drugmaker allocates its resources. The plan, announced by chief executive

Baxter International Inc. has voluntarily recalled a lot of antibiotic intravenous bags after cardboard particles were discovered inside the solution. The recall targets Lot LD175708, expiring 14-Feb 2027, of Cefazolin in Dextrose

Johnson & Johnson (JNJ) has proposed a $5.5 billion settlement to resolve approximately 76,000 ovarian cancer lawsuits filed at both the multi-district litigation and state levels. Law firms representing 99.75% of plaintiffs